A unified lead-oriented synthesis of over fifty molecular scaffolds.

Controlling the properties of lead molecules is critical in drug discovery, but sourcing large numbers of lead-like compounds for screening collections is a major challenge. A unified synthetic approach is described that enabled the synthesis of 52 diverse lead-like molecular scaffolds from a minimal set of 13 precursors. The divergent approach exploited a suite of robust, functional group-tolerant transformations. Crucially, after derivatisation, these scaffolds would target significant lead-like chemical space, and complement commercially-available compounds.

[1]  S. You,et al.  Iridium-Catalyzed Asymmetric Allylic Substitution , 2010 .

[2]  G. V. Paolini,et al.  Quantifying the chemical beauty of drugs. , 2012, Nature chemistry.

[3]  P. Hofmann,et al.  Molecular Catalysts : structure and functional design , 2014 .

[4]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[5]  G. Helmchen,et al.  Iridium-catalyzed asymmetric allylic substitutions--very high regioselectivity and air stability with a catalyst derived from dibenzo[a,e]cyclooctatetraene and a phosphoramidite. , 2008, Angewandte Chemie.

[6]  Olivier Sperandio,et al.  Rationalizing the chemical space of protein-protein interaction inhibitors. , 2010, Drug discovery today.

[7]  C. Humblet,et al.  Escape from flatland: increasing saturation as an approach to improving clinical success. , 2009, Journal of medicinal chemistry.

[8]  Jerome Wielens,et al.  Oncogenic protein interfaces: small molecules, big challenges , 2014, Nature Reviews Cancer.

[9]  Tudor I. Oprea,et al.  Is There a Difference between Leads and Drugs? A Historical Perspective , 2001, J. Chem. Inf. Comput. Sci..

[10]  Ryan G. Coleman,et al.  ZINC: A Free Tool to Discover Chemistry for Biology , 2012, J. Chem. Inf. Model..

[11]  J. A. Grant,et al.  A modular lead-oriented synthesis of diverse piperazine, 1,4-diazepane and 1,5-diazocane scaffolds. , 2014, Organic & biomolecular chemistry.

[12]  C. Lipinski.  Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.

[13]  Adam Nelson,et al.  Towards the realisation of lead-oriented synthesis. , 2014, Drug discovery today.

[14]  Adam Nelson,et al.  Iridium‐Catalyzed Asymmetric Allylic Amination with Polar Amines: Access to Building Blocks with Lead‐Like Molecular Properties , 2010 .

[15]  J. Wolfe,et al.  Asymmetric palladium-catalyzed carboamination reactions for the synthesis of enantiomerically enriched 2-(arylmethyl)- and 2-(alkenylmethyl)pyrrolidines. , 2010, Journal of the American Chemical Society.

[16]  György M. Keserü,et al.  The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.

[17]  T. Ritchie,et al.  The impact of aromatic ring count on compound developability--are too many aromatic rings a liability in drug design? , 2009, Drug discovery today.

[18]  J. Wolfe,et al.  A concise asymmetric synthesis of cis-2,6-disubstituted N-aryl piperazines via Pd-catalyzed carboamination reactions. , 2007, Organic letters.

[19]  D. Bojanic,et al.  Impact of high-throughput screening in biomedical research , 2011, Nature Reviews Drug Discovery.

[20]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[21]  A. H. Lipkus,et al.  Structural Diversity of Organic Chemistry. a Scaffold Analysis of the Cas Registry , 2022 .

[22]  Adam Nelson,et al.  Synthesis of Natural-Product-Like Molecules with Over Eighty Distinct Scaffolds** , 2008, Angewandte Chemie.

[23]  Alexander Chuprina,et al.  Drug- and Lead-likeness, Target Class, and Molecular Diversity Analysis of 7.9 Million Commercially Available Organic Compounds Provided by 29 Suppliers , 2010, J. Chem. Inf. Model..

[24]  Stefan Wetzel,et al.  The Scaffold Tree - Visualization of the Scaffold Universe by Hierarchical Scaffold Classification , 2007, J. Chem. Inf. Model..

[25]  William Lewis,et al.  Synthesis of natural-product-like scaffolds in unprecedented efficiency via a 12-fold branching pathway , 2011 .

[26]  J. Hartwig,et al.  Mechanistically driven development of iridium catalysts for asymmetric allylic substitution. , 2010, Accounts of chemical research.

[27]  G. G. Stokes.  "J." , 1890, The New Yale Book of Quotations.

[28]  H. Pajouhesh,et al.  Medicinal chemical properties of successful central nervous system drugs , 2005, NeuroRX.

[29]  M. Waring.  Defining optimum lipophilicity and molecular weight ranges for drug candidates-Molecular weight dependent lower logD limits based on permeability. , 2009, Bioorganic & medicinal chemistry letters.

[30]  K. Nicolaou.  Advancing the drug discovery and development process. , 2014, Angewandte Chemie.

[31]  O. Grygorenko,et al.  Toward lead-oriented synthesis: one-pot version of Castagnoli condensation with nonactivated alicyclic anhydrides. , 2014, ACS combinatorial science.

[32]  Frank Glorius,et al.  A robustness screen for the rapid assessment of chemical reactions , 2013, Nature Chemistry.

[33]  Andrew R. Leach,et al.  Molecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery , 2001, J. Chem. Inf. Comput. Sci..

[34]  Emanuele Perola,et al.  An analysis of the binding efficiencies of drugs and their leads in successful drug discovery programs. , 2010, Journal of medicinal chemistry.

[35]  P. Leeson,et al.  A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.

[36]  Didier Rognan,et al.  Assessing the Scaffold Diversity of Screening Libraries , 2006, J. Chem. Inf. Model..

[37]  G. Panda,et al.  I2-mediated diversity oriented diastereoselective synthesis of amino acid derived trans-2,5-disubstituted morpholines, piperazines, and thiomorpholines. , 2012, ACS combinatorial science.

[38]  M. Hann.  Molecular obesity, potency and other addictions in drug discovery , 2011 .

[39]  P. Verhoest,et al.  Defining desirable central nervous system drug space through the alignment of molecular properties, in vitro ADME, and safety attributes. , 2010, ACS chemical neuroscience.

[40]  Channa K. Hattotuwagama,et al.  Lead-oriented synthesis: a new opportunity for synthetic chemistry. , 2012, Angewandte Chemie.

[41]  G. Helmchen.  Ir‐Catalyzed Asymmetric Allylic Substitution Reactions – Fundamentals and Applications in Natural Products Synthesis , 2014 .

[42]  Adam Nelson,et al.  A conceptual framework for analysing and planning synthetic approaches to diverse lead-like scaffolds. , 2013, Chemical communications.

[43]  J. A. Grant,et al.  Modular, gold-catalyzed approach to the synthesis of lead-like piperazine scaffolds. , 2013, Organic letters.

[44]  S. Marsden,et al.  Recent advances and applications of iridium-catalysed asymmetric allylic substitution. , 2012, Organic & biomolecular chemistry.

[45]  David R Spring,et al.  Diversity-oriented synthesis as a tool for the discovery of novel biologically active small molecules. , 2010, Nature communications.